Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 103 | 2023 | 20827 | 3.640 |
Why?
|
Receptor, erbB-2 | 38 | 2023 | 2418 | 2.630 |
Why?
|
Medical Oncology | 12 | 2023 | 2267 | 1.730 |
Why?
|
Quinolines | 13 | 2021 | 732 | 1.700 |
Why?
|
Neoplasms | 23 | 2023 | 21675 | 1.260 |
Why?
|
Receptors, Progesterone | 13 | 2022 | 1098 | 1.260 |
Why?
|
Vulnerable Populations | 5 | 2023 | 685 | 1.220 |
Why?
|
Nitriles | 4 | 2015 | 953 | 1.210 |
Why?
|
Receptors, Estrogen | 14 | 2021 | 2190 | 1.180 |
Why?
|
Quinazolines | 10 | 2016 | 1356 | 1.110 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2021 | 1523 | 1.030 |
Why?
|
Bone Density Conservation Agents | 4 | 2022 | 768 | 0.940 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2023 | 11524 | 0.920 |
Why?
|
Aromatase Inhibitors | 4 | 2017 | 487 | 0.890 |
Why?
|
Chemotherapy, Adjuvant | 31 | 2023 | 3480 | 0.860 |
Why?
|
Triazoles | 3 | 2015 | 904 | 0.840 |
Why?
|
Conflict of Interest | 5 | 2016 | 544 | 0.810 |
Why?
|
Clinical Trials as Topic | 11 | 2021 | 7908 | 0.730 |
Why?
|
Aniline Compounds | 2 | 2014 | 986 | 0.680 |
Why?
|
Bone Neoplasms | 4 | 2022 | 2529 | 0.660 |
Why?
|
Health Services Accessibility | 8 | 2019 | 5136 | 0.660 |
Why?
|
Neoplasm Recurrence, Local | 19 | 2023 | 9239 | 0.640 |
Why?
|
Neoadjuvant Therapy | 8 | 2023 | 2727 | 0.600 |
Why?
|
Industry | 3 | 2016 | 366 | 0.590 |
Why?
|
Delivery of Health Care | 8 | 2023 | 5319 | 0.590 |
Why?
|
Health Care Costs | 4 | 2014 | 3207 | 0.590 |
Why?
|
Androstadienes | 3 | 2017 | 345 | 0.560 |
Why?
|
Financing, Personal | 1 | 2019 | 308 | 0.560 |
Why?
|
Disease-Free Survival | 22 | 2023 | 6895 | 0.540 |
Why?
|
Hormones | 4 | 2024 | 889 | 0.530 |
Why?
|
Protein Kinase Inhibitors | 12 | 2023 | 5532 | 0.530 |
Why?
|
Healthcare Disparities | 6 | 2021 | 3155 | 0.520 |
Why?
|
Diphosphonates | 4 | 2022 | 622 | 0.510 |
Why?
|
Female | 115 | 2023 | 380020 | 0.500 |
Why?
|
Antineoplastic Agents | 14 | 2021 | 13691 | 0.490 |
Why?
|
Patient Participation | 4 | 2019 | 1457 | 0.480 |
Why?
|
Paclitaxel | 10 | 2023 | 1705 | 0.470 |
Why?
|
Health Care Rationing | 2 | 2014 | 437 | 0.460 |
Why?
|
Professional Practice | 2 | 2016 | 326 | 0.460 |
Why?
|
Humans | 143 | 2024 | 743811 | 0.450 |
Why?
|
Travel | 1 | 2019 | 788 | 0.440 |
Why?
|
Peer Review, Research | 1 | 2015 | 329 | 0.430 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 890 | 0.390 |
Why?
|
Research | 2 | 2022 | 1999 | 0.390 |
Why?
|
Mastectomy, Segmental | 6 | 2020 | 956 | 0.380 |
Why?
|
Immunoconjugates | 3 | 2023 | 901 | 0.380 |
Why?
|
Drug Industry | 1 | 2016 | 746 | 0.370 |
Why?
|
Private Sector | 1 | 2013 | 393 | 0.360 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 1100 | 0.360 |
Why?
|
Ontario | 2 | 2022 | 383 | 0.350 |
Why?
|
Geriatrics | 1 | 2014 | 396 | 0.340 |
Why?
|
Neoplasm Staging | 20 | 2021 | 11036 | 0.340 |
Why?
|
Patients | 3 | 2013 | 899 | 0.340 |
Why?
|
Quality of Life | 10 | 2022 | 12788 | 0.310 |
Why?
|
Physician's Role | 1 | 2014 | 942 | 0.300 |
Why?
|
Practice Guidelines as Topic | 2 | 2022 | 7270 | 0.300 |
Why?
|
Survivors | 2 | 2016 | 2291 | 0.290 |
Why?
|
Minority Groups | 2 | 2023 | 1222 | 0.290 |
Why?
|
Quality Assurance, Health Care | 2 | 2014 | 2211 | 0.280 |
Why?
|
Medically Uninsured | 1 | 2012 | 853 | 0.280 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.280 |
Why?
|
Postmenopause | 3 | 2014 | 2458 | 0.280 |
Why?
|
Mastectomy | 8 | 2020 | 1793 | 0.270 |
Why?
|
Middle Aged | 61 | 2023 | 213241 | 0.270 |
Why?
|
Health Care Reform | 2 | 2014 | 1261 | 0.270 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2018 | 1209 | 0.260 |
Why?
|
Camptothecin | 3 | 2023 | 576 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3134 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3241 | 0.260 |
Why?
|
Bone and Bones | 1 | 2016 | 2576 | 0.250 |
Why?
|
Financial Support | 2 | 2016 | 115 | 0.240 |
Why?
|
Pain | 2 | 2017 | 4987 | 0.230 |
Why?
|
Aged | 45 | 2023 | 163178 | 0.230 |
Why?
|
United States | 18 | 2022 | 69859 | 0.230 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 2727 | 0.220 |
Why?
|
Cost of Illness | 3 | 2022 | 1859 | 0.220 |
Why?
|
Disclosure | 2 | 2008 | 737 | 0.220 |
Why?
|
Cross-Cultural Comparison | 1 | 2006 | 651 | 0.220 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2023 | 539 | 0.210 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 841 | 0.210 |
Why?
|
Patient Acceptance of Health Care | 4 | 2018 | 3020 | 0.210 |
Why?
|
Economics, Medical | 1 | 2022 | 113 | 0.210 |
Why?
|
Neoplasm Metastasis | 8 | 2021 | 4848 | 0.200 |
Why?
|
Physicians | 3 | 2016 | 4569 | 0.200 |
Why?
|
Tamoxifen | 1 | 2006 | 981 | 0.200 |
Why?
|
Mammography | 4 | 2010 | 2475 | 0.200 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2020 | 933 | 0.190 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 973 | 0.190 |
Why?
|
Cost-Benefit Analysis | 2 | 2013 | 5388 | 0.190 |
Why?
|
Patient Selection | 4 | 2023 | 4210 | 0.180 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13112 | 0.180 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2020 | 323 | 0.180 |
Why?
|
Decision Support Techniques | 2 | 2012 | 1956 | 0.180 |
Why?
|
Patient Education as Topic | 2 | 2011 | 2278 | 0.180 |
Why?
|
Meningeal Carcinomatosis | 1 | 2020 | 65 | 0.180 |
Why?
|
Brain Neoplasms | 5 | 2020 | 8856 | 0.180 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2000 | 110 | 0.170 |
Why?
|
Mass Screening | 5 | 2020 | 5251 | 0.170 |
Why?
|
BRCA2 Protein | 2 | 2024 | 794 | 0.170 |
Why?
|
Early Detection of Cancer | 2 | 2014 | 3089 | 0.170 |
Why?
|
Decision Making | 5 | 2014 | 3887 | 0.160 |
Why?
|
Quality Improvement | 1 | 2014 | 3750 | 0.160 |
Why?
|
Mutation | 7 | 2021 | 29777 | 0.160 |
Why?
|
Policy | 1 | 2022 | 508 | 0.160 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 250 | 0.160 |
Why?
|
Adult | 44 | 2022 | 213889 | 0.160 |
Why?
|
Survival Rate | 7 | 2020 | 12786 | 0.160 |
Why?
|
BRCA1 Protein | 2 | 2024 | 1148 | 0.150 |
Why?
|
Neutropenia | 2 | 2017 | 895 | 0.150 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2020 | 413 | 0.150 |
Why?
|
Biomedical Research | 3 | 2013 | 3308 | 0.150 |
Why?
|
Prognosis | 11 | 2023 | 29052 | 0.150 |
Why?
|
Appointments and Schedules | 2 | 2014 | 417 | 0.140 |
Why?
|
Treatment Outcome | 23 | 2021 | 63042 | 0.140 |
Why?
|
Breast | 5 | 2023 | 1970 | 0.130 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2022 | 648 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 577 | 0.130 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2021 | 629 | 0.130 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1411 | 0.130 |
Why?
|
Hospice Care | 1 | 2022 | 672 | 0.120 |
Why?
|
Interinstitutional Relations | 2 | 2007 | 240 | 0.120 |
Why?
|
Stomatitis | 1 | 2017 | 267 | 0.120 |
Why?
|
Ticlopidine | 1 | 2000 | 899 | 0.120 |
Why?
|
Imidazoles | 2 | 2017 | 1206 | 0.120 |
Why?
|
Community-Institutional Relations | 1 | 2015 | 204 | 0.120 |
Why?
|
Follow-Up Studies | 15 | 2020 | 39001 | 0.120 |
Why?
|
Nurse Practitioners | 1 | 2017 | 269 | 0.120 |
Why?
|
Bone Marrow Neoplasms | 1 | 2014 | 104 | 0.120 |
Why?
|
Boston | 4 | 2021 | 9310 | 0.120 |
Why?
|
Stroke Volume | 4 | 2018 | 5002 | 0.120 |
Why?
|
Organizational Affiliation | 1 | 2013 | 33 | 0.120 |
Why?
|
Patient Care | 1 | 2019 | 638 | 0.110 |
Why?
|
Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
Aged, 80 and over | 15 | 2023 | 57744 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2011 | 3921 | 0.110 |
Why?
|
Cell Cycle | 2 | 2020 | 2963 | 0.110 |
Why?
|
Prospective Studies | 11 | 2023 | 53250 | 0.110 |
Why?
|
Health Policy | 2 | 2015 | 2662 | 0.100 |
Why?
|
Pilot Projects | 5 | 2023 | 8316 | 0.100 |
Why?
|
Drug Administration Schedule | 5 | 2019 | 4931 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2020 | 10940 | 0.100 |
Why?
|
Receptors, Androgen | 1 | 2018 | 1055 | 0.100 |
Why?
|
Amenorrhea | 1 | 2015 | 485 | 0.100 |
Why?
|
Terminal Care | 2 | 2022 | 1694 | 0.100 |
Why?
|
Time Factors | 7 | 2019 | 40038 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 9944 | 0.100 |
Why?
|
Indoles | 2 | 1990 | 1841 | 0.100 |
Why?
|
Massachusetts | 2 | 2019 | 8660 | 0.100 |
Why?
|
Cancer Care Facilities | 1 | 2014 | 402 | 0.100 |
Why?
|
Universities | 2 | 2008 | 951 | 0.090 |
Why?
|
Medicaid | 2 | 2014 | 2736 | 0.090 |
Why?
|
Medicare | 2 | 2022 | 6565 | 0.090 |
Why?
|
Program Evaluation | 1 | 2019 | 2483 | 0.090 |
Why?
|
Survival Analysis | 7 | 2019 | 10251 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6539 | 0.090 |
Why?
|
Radiation Oncology | 1 | 2016 | 555 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8385 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1722 | 0.090 |
Why?
|
Income | 1 | 2019 | 1913 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2110 | 0.090 |
Why?
|
Guidelines as Topic | 1 | 2016 | 1404 | 0.090 |
Why?
|
Leucomycins | 1 | 1989 | 3 | 0.090 |
Why?
|
Lymph Nodes | 3 | 2019 | 3476 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2007 | 1660 | 0.080 |
Why?
|
Retreatment | 2 | 2021 | 609 | 0.080 |
Why?
|
Disease Progression | 2 | 2023 | 13273 | 0.080 |
Why?
|
Choice Behavior | 2 | 2019 | 802 | 0.080 |
Why?
|
Diarrhea | 2 | 2020 | 1348 | 0.080 |
Why?
|
Health Care Surveys | 2 | 2018 | 2453 | 0.080 |
Why?
|
Ventricular Function, Left | 3 | 2018 | 3660 | 0.080 |
Why?
|
Double-Blind Method | 5 | 2023 | 12020 | 0.080 |
Why?
|
Aspirin | 1 | 2020 | 3283 | 0.080 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2008 | 129 | 0.080 |
Why?
|
History, 21st Century | 1 | 2014 | 1532 | 0.080 |
Why?
|
Psychometrics | 2 | 2014 | 3000 | 0.080 |
Why?
|
Breast Neoplasms, Male | 2 | 2020 | 210 | 0.080 |
Why?
|
Cyclophosphamide | 4 | 2022 | 2241 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 35409 | 0.080 |
Why?
|
Antibodies, Monoclonal | 5 | 2017 | 9272 | 0.080 |
Why?
|
Advance Directives | 1 | 2009 | 246 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2000 | 3070 | 0.070 |
Why?
|
Nausea | 2 | 2020 | 674 | 0.070 |
Why?
|
Tobacco Industry | 1 | 2008 | 126 | 0.070 |
Why?
|
Risk Assessment | 6 | 2020 | 23327 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3583 | 0.070 |
Why?
|
Melanoma, Experimental | 1 | 1990 | 560 | 0.070 |
Why?
|
Troponin I | 1 | 2011 | 619 | 0.070 |
Why?
|
Financing, Organized | 1 | 2008 | 202 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5170 | 0.070 |
Why?
|
Telemedicine | 1 | 2023 | 2874 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2019 | 13980 | 0.070 |
Why?
|
Retrospective Studies | 12 | 2023 | 77410 | 0.070 |
Why?
|
Drug Costs | 1 | 2014 | 1105 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 8430 | 0.070 |
Why?
|
Societies, Medical | 1 | 2017 | 3740 | 0.070 |
Why?
|
Social Values | 1 | 2006 | 224 | 0.060 |
Why?
|
Genotype | 4 | 2023 | 12944 | 0.060 |
Why?
|
Feasibility Studies | 4 | 2023 | 5078 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1989 | 690 | 0.060 |
Why?
|
Heart Diseases | 2 | 2009 | 2789 | 0.060 |
Why?
|
Organizational Policy | 1 | 2007 | 428 | 0.060 |
Why?
|
Drug Resistance | 2 | 1990 | 1606 | 0.060 |
Why?
|
Health Status Disparities | 1 | 2016 | 1796 | 0.060 |
Why?
|
Spouse Abuse | 1 | 2006 | 178 | 0.060 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2074 | 0.060 |
Why?
|
Filgrastim | 3 | 2010 | 133 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 12354 | 0.060 |
Why?
|
Piperazines | 3 | 2020 | 2487 | 0.060 |
Why?
|
Poverty | 1 | 2016 | 2660 | 0.060 |
Why?
|
Life Style | 1 | 2016 | 3833 | 0.060 |
Why?
|
Research Support as Topic | 1 | 2008 | 705 | 0.060 |
Why?
|
Male | 13 | 2023 | 349776 | 0.060 |
Why?
|
Attitude to Death | 1 | 2006 | 382 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4839 | 0.060 |
Why?
|
Continuity of Patient Care | 2 | 2021 | 1049 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2009 | 2971 | 0.060 |
Why?
|
Hospitals, Teaching | 1 | 2007 | 1180 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 68 | 0.050 |
Why?
|
Culture | 1 | 2006 | 632 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2019 | 1770 | 0.050 |
Why?
|
Cohort Studies | 6 | 2023 | 40545 | 0.050 |
Why?
|
Prejudice | 1 | 2006 | 569 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 1 | 2008 | 1203 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 644 | 0.050 |
Why?
|
Focus Groups | 1 | 2006 | 1320 | 0.050 |
Why?
|
Estrogens | 1 | 2008 | 1563 | 0.050 |
Why?
|
Gastroesophageal Reflux | 1 | 2008 | 782 | 0.050 |
Why?
|
Tumor Burden | 2 | 2019 | 1917 | 0.050 |
Why?
|
Adenosine Diphosphate | 1 | 2022 | 425 | 0.050 |
Why?
|
Erythropoietin | 1 | 2005 | 726 | 0.050 |
Why?
|
Gene Amplification | 2 | 2019 | 1063 | 0.050 |
Why?
|
Professional-Patient Relations | 1 | 2006 | 737 | 0.050 |
Why?
|
Blood-Brain Barrier | 1 | 2007 | 1018 | 0.050 |
Why?
|
Schools, Medical | 1 | 2007 | 879 | 0.050 |
Why?
|
Administration, Oral | 2 | 2019 | 3912 | 0.050 |
Why?
|
Receptor, erbB-3 | 1 | 2021 | 142 | 0.050 |
Why?
|
Costs and Cost Analysis | 2 | 2018 | 1680 | 0.050 |
Why?
|
Mammaplasty | 1 | 2011 | 1204 | 0.050 |
Why?
|
Cross-Sectional Studies | 6 | 2021 | 25032 | 0.050 |
Why?
|
SEER Program | 2 | 2016 | 1507 | 0.050 |
Why?
|
Risk Factors | 6 | 2022 | 72252 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 323 | 0.040 |
Why?
|
Data Collection | 1 | 2009 | 3339 | 0.040 |
Why?
|
Plasmapheresis | 1 | 2000 | 211 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12954 | 0.040 |
Why?
|
Carcinoma | 1 | 2011 | 2375 | 0.040 |
Why?
|
Doxorubicin | 4 | 2010 | 2234 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3778 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 666 | 0.040 |
Why?
|
Polyethylene Glycols | 3 | 2010 | 1181 | 0.040 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3617 | 0.040 |
Why?
|
Insurance Coverage | 2 | 2021 | 1900 | 0.040 |
Why?
|
Endometrial Neoplasms | 1 | 2007 | 1350 | 0.040 |
Why?
|
Phthalazines | 1 | 2020 | 359 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2019 | 513 | 0.040 |
Why?
|
Radiotherapy | 2 | 2015 | 1533 | 0.040 |
Why?
|
Chromatin | 1 | 1989 | 2931 | 0.040 |
Why?
|
Clodronic Acid | 1 | 2017 | 58 | 0.040 |
Why?
|
Prescription Fees | 1 | 2018 | 146 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6363 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2019 | 2944 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 2649 | 0.040 |
Why?
|
Vomiting | 1 | 2020 | 636 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 2575 | 0.040 |
Why?
|
Pyridines | 2 | 2019 | 2827 | 0.040 |
Why?
|
Recurrence | 2 | 2019 | 8337 | 0.030 |
Why?
|
Abdominal Neoplasms | 1 | 2018 | 292 | 0.030 |
Why?
|
Professional Practice Location | 1 | 2016 | 58 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1502 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2023 | 1372 | 0.030 |
Why?
|
Fasting | 1 | 2022 | 1590 | 0.030 |
Why?
|
Patient Compliance | 1 | 2006 | 2683 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1619 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3229 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 1988 | 0.030 |
Why?
|
Angina, Unstable | 1 | 2000 | 926 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2327 | 0.030 |
Why?
|
Communication | 1 | 2009 | 3748 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2052 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3281 | 0.030 |
Why?
|
Craniotomy | 1 | 2019 | 729 | 0.030 |
Why?
|
DNA | 1 | 1989 | 7295 | 0.030 |
Why?
|
Databases, Factual | 3 | 2015 | 7729 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1530 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2010 | 6620 | 0.030 |
Why?
|
Purines | 1 | 2017 | 590 | 0.030 |
Why?
|
Central Nervous System | 1 | 2021 | 1358 | 0.030 |
Why?
|
Ownership | 1 | 2016 | 332 | 0.030 |
Why?
|
Aminopyridines | 1 | 2017 | 543 | 0.030 |
Why?
|
Japan | 1 | 2017 | 1360 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 685 | 0.030 |
Why?
|
Socioeconomic Factors | 3 | 2018 | 7784 | 0.030 |
Why?
|
Young Adult | 5 | 2018 | 56392 | 0.030 |
Why?
|
Age Factors | 4 | 2017 | 18355 | 0.030 |
Why?
|
Drug Interactions | 1 | 2017 | 1460 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2018 | 1117 | 0.030 |
Why?
|
Mental Health | 1 | 2006 | 3012 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2017 | 850 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9440 | 0.030 |
Why?
|
Comorbidity | 1 | 2006 | 10380 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2020 | 2307 | 0.030 |
Why?
|
Fear | 1 | 2020 | 1438 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4183 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2022 | 15518 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1373 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2924 | 0.020 |
Why?
|
Nogalamycin | 1 | 1990 | 2 | 0.020 |
Why?
|
Leukemia P388 | 1 | 1990 | 16 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2950 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3530 | 0.020 |
Why?
|
Social Support | 1 | 2020 | 2118 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 6773 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1002 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 162 | 0.020 |
Why?
|
Models, Biological | 1 | 2006 | 9582 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2281 | 0.020 |
Why?
|
Cardiac Electrophysiology | 1 | 2009 | 49 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2274 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2006 | 4254 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2009 | 0.020 |
Why?
|
Sirolimus | 1 | 2017 | 1565 | 0.020 |
Why?
|
Circular Dichroism | 1 | 1989 | 353 | 0.020 |
Why?
|
Propensity Score | 1 | 2015 | 1781 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9848 | 0.020 |
Why?
|
Chief Executive Officers, Hospital | 1 | 2007 | 9 | 0.020 |
Why?
|
Adolescent | 4 | 2021 | 85729 | 0.020 |
Why?
|
Stents | 1 | 2000 | 3280 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13404 | 0.020 |
Why?
|
Karyotyping | 1 | 1990 | 1243 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3591 | 0.020 |
Why?
|
Nonprescription Drugs | 1 | 2008 | 116 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2177 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2617 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1799 | 0.020 |
Why?
|
Palliative Care | 1 | 2022 | 3490 | 0.020 |
Why?
|
Incidence | 2 | 2015 | 20948 | 0.020 |
Why?
|
Sodium Chloride | 1 | 1989 | 625 | 0.020 |
Why?
|
Registries | 2 | 2017 | 8090 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3917 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9677 | 0.020 |
Why?
|
Child | 1 | 2014 | 77637 | 0.020 |
Why?
|
Cell Division | 2 | 1990 | 4568 | 0.020 |
Why?
|
Biological Transport | 1 | 1990 | 2119 | 0.020 |
Why?
|
Goals | 1 | 2011 | 708 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2008 | 20121 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2017 | 3391 | 0.020 |
Why?
|
Hospitalization | 1 | 2023 | 10259 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8637 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 16674 | 0.010 |
Why?
|
Gift Giving | 1 | 2004 | 80 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1683 | 0.010 |
Why?
|
Cell Survival | 2 | 1990 | 5881 | 0.010 |
Why?
|
Cultural Characteristics | 1 | 2004 | 261 | 0.010 |
Why?
|
Administrative Personnel | 1 | 2004 | 187 | 0.010 |
Why?
|
Mice | 4 | 2018 | 81154 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3608 | 0.010 |
Why?
|
Kinetics | 1 | 1990 | 6476 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25609 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1990 | 6311 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4036 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3439 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12243 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 2005 | 565 | 0.010 |
Why?
|
Faculty | 1 | 2004 | 386 | 0.010 |
Why?
|
Body Mass Index | 2 | 2008 | 12718 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6593 | 0.010 |
Why?
|
Faculty, Medical | 1 | 2007 | 1181 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2505 | 0.010 |
Why?
|
Histones | 1 | 1989 | 2598 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15211 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6750 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6457 | 0.010 |
Why?
|
Animals | 4 | 2018 | 168660 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17439 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2004 | 2538 | 0.010 |
Why?
|
Educational Status | 1 | 2004 | 2540 | 0.010 |
Why?
|
Cell Line | 1 | 1990 | 15993 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19894 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23398 | 0.010 |
Why?
|
Brain | 1 | 2019 | 26345 | 0.010 |
Why?
|
Menogaril | 1 | 1990 | 4 | 0.010 |
Why?
|
Verapamil | 1 | 1990 | 244 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2004 | 15067 | 0.000 |
Why?
|
Glutathione | 1 | 1990 | 590 | 0.000 |
Why?
|
Drug Synergism | 1 | 1990 | 1794 | 0.000 |
Why?
|
Algorithms | 1 | 2005 | 13869 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1990 | 19232 | 0.000 |
Why?
|